Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Hematology. American Society of Hematology. Education Program
|
December 7, 2024
When should we use it? The role of brentuximab vedotin in 2024
Joseph G Schroers-Martin, Ranjana Advani
JCO Oncology Practice
|
September 12, 2024
Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma
Joseph G Schroers-Martin, Ranjana Advani
Clinical Lymphoma, Myeloma & Leukemia
|
June 4, 2026
Early Stage Hodgkin Lymphoma-Are We Ready for Novel Agents?
Joseph G Schroers-Martin, Ranjana Advani
JCO Oncology Practice
|
November 12, 2024
Cell-Free DNA in Hematologic Malignancies
Joseph G Schroers-Martin, Ash A Alizadeh
Seminars in Hematology
|
July 14, 2024
The role of response adapted therapy in the era of novel agents
Joseph G Schroers-Martin, Ranjana H Advani
Annual Review of Pathology
|
September 21, 2022
Molecular Monitoring of Lymphomas
Joseph G Schroers-Martin, Stefan Alig, Andrea Garofalo, et al.
Haematologica
|
July 2, 2026
Anti-CD47 antibody magrolimab with pembrolizumab in patients with relapsed / refractory classic Hodgkin lymphoma
Joseph G Schroers-Martin, Reid Merryman, Michael A Spinner, et al.
Cell Stem Cell
|
February 25, 2024
A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment
Jenna M Kastenschmidt, Joseph G Schroers-Martin, Brian J Sworder, et al.
Cancer Discovery
|
March 20, 2023
Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors
Joseph G Schroers-Martin, Joanne Soo, Gabriel Brisou, et al.
Blood Cancer Discovery
|
January 11, 2022
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
Tanaya Shree, Vishnu Shankar, Julian J K Lohmeyer, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Hematology. American Society of Hematology. Education Program
|
December 7, 2024
When should we use it? The role of brentuximab vedotin in 2024
Joseph G Schroers-Martin, Ranjana Advani
JCO Oncology Practice
|
September 12, 2024
Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma
Joseph G Schroers-Martin, Ranjana Advani
Clinical Lymphoma, Myeloma & Leukemia
|
June 4, 2026
Early Stage Hodgkin Lymphoma-Are We Ready for Novel Agents?
Joseph G Schroers-Martin, Ranjana Advani
JCO Oncology Practice
|
November 12, 2024
Cell-Free DNA in Hematologic Malignancies
Joseph G Schroers-Martin, Ash A Alizadeh
Seminars in Hematology
|
July 14, 2024
The role of response adapted therapy in the era of novel agents
Joseph G Schroers-Martin, Ranjana H Advani
Annual Review of Pathology
|
September 21, 2022
Molecular Monitoring of Lymphomas
Joseph G Schroers-Martin, Stefan Alig, Andrea Garofalo, et al.
Haematologica
|
July 2, 2026
Anti-CD47 antibody magrolimab with pembrolizumab in patients with relapsed / refractory classic Hodgkin lymphoma
Joseph G Schroers-Martin, Reid Merryman, Michael A Spinner, et al.
Cell Stem Cell
|
February 25, 2024
A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment
Jenna M Kastenschmidt, Joseph G Schroers-Martin, Brian J Sworder, et al.
Cancer Discovery
|
March 20, 2023
Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors
Joseph G Schroers-Martin, Joanne Soo, Gabriel Brisou, et al.
Blood Cancer Discovery
|
January 11, 2022
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
Tanaya Shree, Vishnu Shankar, Julian J K Lohmeyer, et al.
Page
of 2